148 related articles for article (PubMed ID: 2866230)
1. Comparative chronic effects of buspirone or neuroleptics on rat brain dopaminergic neurotransmission.
McMillen BA
J Neural Transm; 1985; 64(1):1-12. PubMed ID: 2866230
[TBL] [Abstract][Full Text] [Related]
2. Effects of BMY 14802, a potential antipsychotic drug, on rat brain dopaminergic function.
Matthews RT; McMillen BA; Sallis R; Blair D
J Pharmacol Exp Ther; 1986 Oct; 239(1):124-31. PubMed ID: 2876091
[TBL] [Abstract][Full Text] [Related]
3. Acute and subchronic effects of MJ-13859, a potential antipsychotic drug, on rat brain dopaminergic function.
McMillen BA
J Pharmacol Exp Ther; 1985 May; 233(2):369-75. PubMed ID: 2987476
[TBL] [Abstract][Full Text] [Related]
4. Comparative neuropharmacology of buspirone and MJ-13805, a potential anti-anxiety drug.
McMillen BA; Mattiace LA
J Neural Transm; 1983; 57(4):255-65. PubMed ID: 6140299
[TBL] [Abstract][Full Text] [Related]
5. Selective effects of buspirone and molindone on dopamine metabolism and function in the striatum and frontal cortex of the rat.
McMillen BA; McDonald CC
Neuropharmacology; 1983 Mar; 22(3):273-8. PubMed ID: 6133232
[TBL] [Abstract][Full Text] [Related]
6. Presynaptic control of dopamine metabolism in the nucleus accumbens. Lack of effect of buspirone as demonstrated using in vivo voltammetry.
Louilot A; Le Moal M; Simon H
Life Sci; 1987 May; 40(20):2017-24. PubMed ID: 3573992
[TBL] [Abstract][Full Text] [Related]
7. Changes in rat striatal dopamine turnover and receptor activity during one years neuroleptic administration.
Clow A; Theodorou A; Jenner P; Marsden CD
Eur J Pharmacol; 1980 May; 63(2-3):135-44. PubMed ID: 6103813
[TBL] [Abstract][Full Text] [Related]
8. Buspirone: a potential atypical neuroleptic.
Wood PL; Nair NP; Lal S; Etienne P
Life Sci; 1983 Jul; 33(3):269-73. PubMed ID: 6135133
[TBL] [Abstract][Full Text] [Related]
9. Effect of buspirone on rat plasma prolactin levels and striatal dopamine turnover.
Meltzer HY; Simonovic M; Fang VS; Gudelsky GA
Psychopharmacology (Berl); 1982; 78(1):49-53. PubMed ID: 6128756
[TBL] [Abstract][Full Text] [Related]
10. Cerebral dopamine function in rats following withdrawal from one year of continuous neuroleptic administration.
Clow A; Theodorou A; Jenner P; Marsden CD
Eur J Pharmacol; 1980 May; 63(2-3):145-57. PubMed ID: 6103814
[TBL] [Abstract][Full Text] [Related]
11. Dopaminergic effects of buspirone, a novel anxiolytic agent.
Cimino M; Ponzio F; Achilli G; Vantini G; Perego C; Algeri S; Garattini S
Biochem Pharmacol; 1983 Mar; 32(6):1069-74. PubMed ID: 6838654
[TBL] [Abstract][Full Text] [Related]
12. Effects of gepirone, an aryl-piperazine anxiolytic drug, on aggressive behavior and brain monoaminergic neurotransmission.
McMillen BA; Scott SM; Williams HL; Sanghera MK
Naunyn Schmiedebergs Arch Pharmacol; 1987 Apr; 335(4):454-64. PubMed ID: 2439924
[TBL] [Abstract][Full Text] [Related]
13. Disinhibitory effects of buspirone and low doses of sulpiride and haloperidol in two experimental anxiety models in rats: possible role of dopamine.
Pich EM; Samanin R
Psychopharmacology (Berl); 1986; 89(1):125-30. PubMed ID: 2874581
[TBL] [Abstract][Full Text] [Related]
14. Relationship between dopamine receptor occupation by spiperone and acetylcholine levels in the rat striatum after long-term haloperidol treatment depends on dopamine innervation.
Korf J; Sebens JB
J Neurochem; 1987 Feb; 48(2):516-21. PubMed ID: 2878979
[TBL] [Abstract][Full Text] [Related]
15. Dopamine receptor antagonism by the novel antianxiety drug, buspirone.
McMillen BA; Matthews RT; Sanghera MK; Shepard PD; German DC
J Neurosci; 1983 Apr; 3(4):733-8. PubMed ID: 6131948
[No Abstract] [Full Text] [Related]
16. Repeated administration of HA-966 and haloperidol to rats: similar tolerance to striatal dopamine accumulation after HA-966 challenge, but dissimilar effects on striatal [3H]spiperone binding.
Van der Krogt JA; Van Valkenburg CF; Belfroid RD; Heerkens CB
Eur J Pharmacol; 1988 Dec; 158(1-2):29-35. PubMed ID: 3220118
[TBL] [Abstract][Full Text] [Related]
17. Neurochemical effects of buspirone, a novel psychotropic drug, on the central cholinergic system.
Kolasa K; Fusi R; Garattini S; Consolo S; Ladinsky H
J Pharm Pharmacol; 1982 May; 34(5):314-7. PubMed ID: 6123570
[TBL] [Abstract][Full Text] [Related]
18. A study of the effects of buspirone, BMY 13805, and 1-PP on dopaminergic metabolism in the nucleus accumbens using in vivo voltammetry in freely moving rats.
Louilot A; Le Moal M; Simon H
Life Sci; 1986 Aug; 39(8):685-92. PubMed ID: 2874469
[TBL] [Abstract][Full Text] [Related]
19. Effects of intermittent and continuous haloperidol administration on the dopaminergic system in the rat brain.
Kashihara K; Sato M; Fujiwara Y; Harada T; Ogawa T; Otsuki S
Biol Psychiatry; 1986 Jun; 21(7):650-6. PubMed ID: 3011131
[TBL] [Abstract][Full Text] [Related]
20. Effect of acute administration of the 5-HT1A receptor ligand, lesopitron, on rat cortical 5-HT and dopamine turnover.
Ballarín M; Carceller A; Guitart X
Br J Pharmacol; 1994 Oct; 113(2):425-30. PubMed ID: 7530571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
